Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
Obinutuzumab in Primary FSGS
- Conditions
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT04983888
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT04970901
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT04963296
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸Unity Health - White County Medical Center- Rheumatology, Searcy, Arkansas, United States
🇺🇸Providence Medical Foundation, Fullerton, California, United States
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Meir Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT04934930
- Locations
- 🇮🇱
Meir medical center, Kfar Saba, Israel
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 OVERALL
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Target Recruit Count
- 124
- Registration Number
- NCT04920968
- Locations
- 🇵🇱
Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego, Kraków, Poland
🇵🇱Oddział Hematologiczny Z Oddziałem Nowotworów Krwi Dolnośląskie Centrum Transplantacji Komórkowych Z Krajowym Bankiem Dawców Szpiku, Wrocław, Poland
🇵🇱Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego, Białystok, Poland
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 75
- Registration Number
- NCT04895436
- Locations
- 🇮🇹
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 229504, Torino, Piemonte, Italy
🇬🇧Blackpool Victoria Hospital /ID# 267280, Blackpool, Lancashire, United Kingdom
🇺🇸Des Moines Oncology Research Association /ID# 232606, Des Moines, Iowa, United States
CAR-T Followed by Bispecific Antibodies
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT04889716
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- NeoTX Therapeutics Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT04880863
- Locations
- 🇺🇸
NeoTX - 10312, El Paso, Texas, United States
🇺🇸NeoTX - 10310, Tyler, Texas, United States
🇺🇸NeoTX - 10308, Austin, Texas, United States
Avo in R/R and Previously Untreated MCL
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Austin I Kim
- Target Recruit Count
- 53
- Registration Number
- NCT04855695
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safe Accelerated Venetoclax Escalation in CLL
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04843904
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.